I would like to take a moment to put context around our launch of OFIRMEV. As of June 30, 2012 we sold a total of 3.1 million doses of OFIRMEV since the product launched in January of 2011. When compared to available data on comparable new hospital product launches during the past five years that we have reviewed, on average approximately nine times as many doses of OFIRMEV was sold and doses of those products during the first 18 months after launch. We believe this creates a strong base of OFIRMEV users that will continue to drive growth.At this point, I would like to turn the call over to Scott who will discuss our commercial operations and sales performance during the second quarter.
Cadence Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts